Gilead Sciences Inc sell Traumtanz
Start price
20.05.20
/
50%
€66.80
Target price
25.05.20
€60.00
Performance (%)
4.09%
End price
25.05.20
€69.53
Summary
This prediction ended on 25.05.20 with a price of €69.53. The SELL prediction by Traumtanz shows the price for Gilead Sciences Inc slightly increased by 4.09% during the runtime of the prediction. Traumtanz has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Gilead Sciences Inc | -0.800% | -0.800% | -6.719% | 9.921% |
iShares Core DAX® | 3.054% | -1.396% | 15.789% | 12.675% |
iShares Nasdaq 100 | 4.389% | -5.391% | 29.906% | 39.325% |
iShares Nikkei 225® | 5.386% | -3.105% | 16.065% | 8.150% |
iShares S&P 500 | 2.955% | -3.011% | 25.903% | 37.650% |
According to Traumtanz what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Strong uniques
Small Risks for its business
Could be very worthwhile Investment >20% year
Cons
Comments by Traumtanz for this prediction
In the thread Gilead Sciences Inc diskutieren
Sell mit Kursziel 60,0
ValueFreak schrieb am 20.05.20:
Naja, man klammert sich an jeden Strohhalm in der Krise
Bei den ersten acht Patienten
Das sieht mir noch nach einer langen Anlaufzeit aus - jeden Tag kommen 80.000 neu Infizierte hinzu und es ist noch kein globaler R-Wert von 1 erreicht.
Bei den ersten acht Patienten
Das sieht mir noch nach einer langen Anlaufzeit aus - jeden Tag kommen 80.000 neu Infizierte hinzu und es ist noch kein globaler R-Wert von 1 erreicht.
https://www.fiercepharma.com/pharma/gilead-to-start-selling-remdesivir-coming-weeks-expects-multi-year-commercial-opportunity
30.ooo$ pro Behandlung scheint mir nicht gerade günstig...und selbst die anschliessend kolpotierten 4500$ pro Patient weisen in eine Zwei-Klassen-Medizin-Richtung...und ich wie immer skeptisch bei Gilead.
stratec schrieb am 20.05.20:
ValueFreak schrieb am 20.05.20:
Naja, man klammert sich an jeden Strohhalm in der Krise
Bei den ersten acht Patienten
Das sieht mir noch nach einer langen Anlaufzeit aus - jeden Tag kommen 80.000 neu Infizierte hinzu und es ist noch kein globaler R-Wert von 1 erreicht.
Bei den ersten acht Patienten
Das sieht mir noch nach einer langen Anlaufzeit aus - jeden Tag kommen 80.000 neu Infizierte hinzu und es ist noch kein globaler R-Wert von 1 erreicht.
Ihr seid nicht auf dem Laufenden:
Sorrento claims it has COVID-19 cure
ah drum ging Sorrento so ab......aber dann...
Sorrento shares have fallen about 50% from their highs on the news, perhaps raising questions in the market on what Sorrento actually has discovered drug wise. Also worth noting that like other emerging biotech companies, Sorrento isn’t profitable — which adds to the risk profile of the stock. ...
https://finance.yahoo.com/news/sorrento-therapeutics-founder-we-are-not-a-pump-and-dump-scheme-155253179.html
In the thread Trading Gilead Sciences Inc
Sell beendet
Stopped prediction by Traumtanz for Gilead Sciences Inc
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€56.02
06.04.21
06.04.21
€60.00
06.04.22
06.04.22
3.82%
01.07.21
01.07.21
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€48.01
18.12.20
18.12.20
€45.00
-1.78%
23.12.20
23.12.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.30
14.11.20
14.11.20
-
14.11.21
14.11.21
-1.75%
23.11.20
23.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.60
13.11.20
13.11.20
€52.00
1.38%
14.11.20
14.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.00
09.11.20
09.11.20
€55.00
2.66%
10.11.20
10.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€49.75
31.10.20
31.10.20
-
04.11.21
04.11.21
0.53%
09.11.20
09.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€54.61
23.10.20
23.10.20
€55.00
31.10.20
31.10.20
-8.91%
31.10.20
31.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.42
20.10.20
20.10.20
€50.00
22.10.20
22.10.20
-1.26%
22.10.20
22.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.32
26.08.20
26.08.20
€50.00
08.10.20
08.10.20
-2.68%
08.10.20
08.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.59
19.08.20
19.08.20
€52.00
24.08.20
24.08.20
0.76%
24.08.20
24.08.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€67.00
20.06.20
20.06.20
€55.00
03.08.20
03.08.20
-10.91%
03.08.20
03.08.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€77.45
30.04.20
30.04.20
€85.00
04.05.20
04.05.20
-5.28%
04.05.20
04.05.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€74.99
04.04.20
04.04.20
-
18.04.20
18.04.20
5.08%
18.04.20
18.04.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.00
21.03.20
21.03.20
-
04.04.20
04.04.20
3.16%
04.04.20
04.04.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€76.81
19.03.20
19.03.20
€85.00
19.03.20
19.03.20
-3.91%
19.03.20
19.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€64.45
11.03.20
11.03.20
€55.00
11.03.20
11.03.20
0.51%
11.03.20
11.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€72.20
07.03.20
07.03.20
-
10.03.20
10.03.20
-13.56%
10.03.20
10.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€62.32
28.02.20
28.02.20
€58.00
07.03.20
07.03.20
9.27%
07.03.20
07.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€57.14
27.10.19
27.10.19
€50.00
03.02.20
03.02.20
6.00%
03.02.20
03.02.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.93
13.06.19
13.06.19
€45.10
07.08.19
07.08.19
-3.22%
07.08.19
07.08.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€58.18
13.05.19
13.05.19
€45.10
13.06.19
13.06.19
4.48%
13.06.19
13.06.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.99
25.04.19
25.04.19
€45.10
25.04.19
25.04.19
3.20%
25.04.19
25.04.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€77.35
03.02.16
03.02.16
€90.00
09.02.17
09.02.17
-18.07%
09.02.17
09.02.17
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model